Virtus Investment Advisers’s Definium Therapeutics DFTX Stock Holding History

Virtus Investment Advisers’s Portfolio DFTX Stock Details DFTX Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q2	$622K	Sell	13,220 -8,507	-39%	-$210K	0.14%	199
2026 Q1	$411K	Buy	21,727 +529	+2%	+$8.98K	0.11%	242
2025 Q4	$284K	Buy	21,198 +5,611	+36%	+$69.4K	0.08%	265
2025 Q3	$184K	Buy	15,587 +2,706	+21%	+$25.2K	0.05%	265
2025 Q2	$83.6K	Sell	12,881 -10,507	-45%	-$69.1K	0.03%	408
2025 Q1	$137K	Buy	+23,388	New	+$168K	0.04%	360

Other funds holding DFTX

BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return

ACA

Avoro Capital Advisors New York $11.1B AUM 207.82% 1-Year Est. Return

DCM

Driehaus Capital Management Chicago, Illinois $17.3B AUM 211.34% 1-Year Est. Return

Jupiter Topco New York $245B AUM

Capital World Investors Los Angeles, California $846B AUM 46.74% 1-Year Est. Return

Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return

T. Rowe Price Associates Baltimore, Maryland $999B AUM 46.22% 1-Year Est. Return

Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return

State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return

Capital International Investors Los Angeles, California $484B AUM 34.9% 1-Year Est. Return

Virtus Investment Advisers's DFTX Position: Q2 2026 in Review

Virtus Investment Advisers reduced its Definium Therapeutics (DFTX) stake by 39% in Q2 2026, selling an estimated $210K and leaving 13,220 shares worth $622K. The position accounts for 0.14% of the portfolio, ranked #199.

Virtus Investment Advisers first reported a position in DFTX in Q1 2025 and has held it in 6 quarters since. 361 funds tracked by Wall St. Rank hold DFTX as of Q2 2026.

Virtus Investment Advisers held 13,220 shares of Definium Therapeutics worth $622K as of Q2 2026.
Virtus Investment Advisers sold 8,507 Definium Therapeutics shares in Q2 2026, an estimated $210K.
Definium Therapeutics made up 0.14% of Virtus Investment Advisers's portfolio in Q2 2026, its #199 holding.
Virtus Investment Advisers first reported a position in Definium Therapeutics in Q1 2025 and has held it in 6 quarters since.
361 funds tracked by Wall St. Rank held Definium Therapeutics as of Q2 2026.

Based on Virtus Investment Advisers's 13F filing for Q2 2026, filed 11 Aug 2026.